Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fatty Acids Compounds (F.A.G.) Mouthwash is a topical oral rinse formulation developed by researchers at the University of L'Aquila for the treatment of gingivitis and the reduction of dental plaque. The formulation leverages the antimicrobial and anti-inflammatory potential of specific fatty acid compounds to disrupt oral biofilms. Notably, F.A.G. is distinguished from traditional oral antiseptics like chlorhexidine as it is not classified as a conventional antibacterial agent. In a randomized clinical trial (NCT04977778), the mouthwash demonstrated noninferiority to stannous fluoride mouthrinse in reducing plaque accumulation within an experimental gingivitis model, suggesting its utility as an alternative for long-term oral care maintenance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fatty Acids Compounds (F.A.G.) Mouthwash.